Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia

Drugs of Today

Volumn 52, Issue 4, 2016, Pages 249-260

  Del Poeta, G ^a   Postorino, M ^a   Pupo, L ^a   Del Principe, M I ^a   Dal Bo, M ^b   Bittolo, T ^b   Buccisano, F ^a   Mariotti, B ^a   Iannella, E ^a   Maurillo, L ^a   Venditti, A ^a   Gattei, V ^b   de Fabritiis, P ^a   Cantonetti, M ^a   Amadori, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

17p deletion TP53 mutation; ABT 199; Bcl 2; Chronic lymphocytic leukemia; Novel tyrosine kinase inhibitors; Venetoclax

Indexed keywords

BENDAMUSTINE; OBINUTUZUMAB; PROTEIN BCL 2; RITUXIMAB; VENETOCLAX; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; PRECLINICAL STUDY; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84971249960     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2016.52.4.2470954     Document Type: Article

References (77)

1. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N., Pasternack, B.S. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46(2): 219-34.
2. Binet, J.L., Auquier, A., Dighiero, G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48(1): 198-206.
3. Hallek, M., Cheson, B.D., Catovsky, D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12): 5446-56.
4. Tsimberidou, A.M., Keating, M.J. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005, 103(2): 216-28.
5. Dighiero, G., Maloum, K., Desablens, B. et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998, 338(21): 1506-14.
6. Del Poeta, G., Maurillo, L., Venditti, A. et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001, 98(9): 2633-9.
7. Del Principe, M.I., Del Poeta, G., Buccisano, F. et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006, 108(3): 853-61.
8. Gattei, V., Bulian, P., Del Principe, M.I. et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008, 111(2): 865-73.
9. Dohner, H., Stilgenbauer, S., Benner, A. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343(26): 1910-6.
10. Bomben, R., Dal Bo, M., Capello, D. et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol 2009, 144(4): 492-506.
11. Bulian, P., Tarnani, M., Rossi, D. et al. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. Hematol Oncol 2011, 29(2): 91-9.
12. Del Poeta, G., Dal Bo, M., Del Principe, M.I. et al. Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia. Br J Haematol 2013, 160(3): 415-8.
13. Rossi, D., Rasi, S., Spina, V. et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013, 121(8): 1403-12.
14. Hallek, M., Fischer, K., Fingerle-Rowson, G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet 2010, 376(9747): 1164-74.
15. Tam, C.S., O'Brien, S., Wierda, W. et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112(4): 975-80.
16. Eichhorst, B.F., Fink, A.M., Busch, R. et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abts 19.
17. Hillmen, P., Robak, T., Janssens, A. et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015, 385(9980): 1873-83.
18. Goede, V., Fischer, K., Busch, R. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014, 370(12): 1101-10.
19. Catovsky, D., Richards, S., Matutes, E. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370(9583): 230-9.
20. Oscier, D.G., Rose-Zerilli, M.J., Winkelmann, N. et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013, 121(3): 468-75.
21. Stilgenbauer, S., Schnaiter, A., Paschka, P. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014, 123(21): 3247-54.
22. Bosch, F., Abrisqueta, P., Villamor, N. et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009, 27(27): 4578-84.
23. Lamanna, N., Kalaycio, M., Maslak, P. et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006, 24(10): 1575-81.
24. Jones, J.A., Byrd, J.C. How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 2014, 123(10): 1455-60.
25. Souers, A.J., Leverson, J.D., Boghaert, E.R. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19(2): 202-8.
26. Stevenson, F.K., Krysov, S., Davies, A.J., Steele, A.J., Packham, G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118(16): 4313-20.
27. Byrd, J.C., Furman, R.R., Coutre, S.E. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369(1): 32-42.
28. Brown, J.R., Byrd, J.C., Coutre, S.E. et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014, 123(22): 3390-7.
29. Furman, R.R., Sharman, J.P., Coutre, S.E. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370(11): 997-1007.
30. O'Brien, S., Lamanna, N., Kipps, T.J. et al. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014, 124(21): Abst 1994.
31. Farooqui, M.Z., Valdez, J., Martyr, S. et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015, 16(2): 169-76.
32. Byrd, J.C., Brown, J.R., O'Brien, S. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014, 371(3): 213-23.
33. O'Brien, S., Furman, R.R., Coutre, S.E. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014, 15(1): 48-58.
34. O'Brien, S., Jones, J.A., Coutre, S.E. et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: Results from the phase II RESONATE™-17 trial. Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 327.
35. Byrd, J.C., Furman, R.R., Coutre, S.E. et al. Three-year followup of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015, 125(16): 2497-506.
36. Sharman, J.P., Coutre, S.E., Furman, R.R. et al. Second interim analysis of a phase 3 study of idelalisib (Zydelig®) plus rituximab® for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 330.
37. Woyach, J.A., Furman, R.R., Liu, T.M. et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014, 370(24): 2286-94.
38. Furman, R.R., Cheng, S., Lu, P. et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 2014, 370(24): 2352-4.
39. Ruella, M., Barrett, D., Kenderian, S.S. et al. Novel chimeric antigen receptor T cells for the treatment of CD19-negative relapses occurring after CD19-targeted immunotherapies. Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 966.
40. Wu, J., Fu, J., Zhang, M., Liu, D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol 2015, 8: 104.
41. Tsujimoto, Y., Finger, L.R., Yunis, J., Nowell, P.C., Croce, C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984, 226(4678): 1097-9.
42. Tsujimoto, Y., Shimizu, S. Bcl-2 family: life-or-death switch. FEBS Lett 2000, 466(1): 6-10.
43. Tsujimoto, Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 1998, 3(11): 697-707.
44. Cory, S., Huang, D.C., Adams, J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22(53): 8590-607.
45. Susin, S.A., Zamzami, N., Castedo, M. et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996, 184(4): 1331-41.
46. Kluck, R.M., Bossy-Wetzel, E., Green, D.R., Newmeyer, D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997, 275(5303): 1132-6.
47. Adams, J.M., Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281(5381): 1322-6.
48. Kelekar, A., Thompson, C.B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998, 8(8): 324-30.
49. James, D.F., Castro, J.E., Loria, O., Prada, C.E., Aguillon, R.A., Kipps, T.J. AT-101, a small molecule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trial. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 2-6, Atlanta) 2006] 2006, 24(Suppl. 18): Abst 6605.
50. van Delft, M.F., Wei, A.H., Mason, K.D. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10(5): 389-99.
51. Roberts, A.W., Seymour, J.F., Brown, J.R. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012, 30(5): 488-96.
52. Zhang, H., Nimmer, P.M., Tahir, S.K. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007, 14(5): 943-51.
53. Wilson, W.H., O'Connor, O.A., Czuczman, M.S. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010, 11(12): 1149-59.
54. Czabotar, P.E., Lessene, G., Strasser, A., Adams, J.M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014, 15(1): 49-63.
55. Vogler, M., Dinsdale, D., Dyer, M.J., Cohen, G.M. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol 2013, 163(1): 139-42.
56. Khaw, S.L., Merino, D., Anderson, M.A., Glaser, S.P., Bouillet, P., Roberts, A.W., Huang, D.C. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia 2014, 28(6): 1207-15.
57. Pan, R., Hogdal, L.J., Benito, J.M. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014, 4(3): 362-75.
58. Bodo, J., Zhao, X., Smith, M.R., Hsi, E.D. Activity of ABT-199 and acquired resistance in follicular lymphoma cells. Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 3635.
59. Portell, C.A., Axelrod, M., Brett, L.K. et al. Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT- 199(GDC-0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): Molecular analysis reveals mechanisms of target interactions. Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 509.
60. Parikh, K., Cang, S., Sekhri, A., Liu, D. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol 2014, 7: 78.
61. Tabe, Y., Harada, M., Miyamae, Y. et al. Selective inhibitor of nuclear export selinexor (KPT-330) and BCL2 inhibitor ABT-199 enhance the anti-lymphoma effect of BTK inhibitor ibrutinib in mantle cell lymphoma. 56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 2254.
62. Klanova, M., Andera, L., Soukup, J. et al. MCL1 targeting agent homoharringtonine exerts strong cytotoxicity towards diffuse large B-cell lymphoma (DLBCL) cells and synergizes with BCL2 targeting agent ABT199 in eliminating BCL2-positive DLBCL cells. Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 3645.
63. Seymour, J.F., Davids, M.S., Pagel, J.M. et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood [55th Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013] 2013, 122(21): Abst 872.
64. Ghia, P., Hallek, M. Management of chronic lymphocytic leukemia. Haematologica 2014, 99(6): 965-72.
65. Seymour, J.F., Davids, M.S., Pagel, J.M. et al. ABT-199 (GDC- 0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control. 50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014] 2014, Abst 7015.
66. Davids, M.S., Seymour, J.F., Gerecitano, J.F. et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. 50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014, Abst 8522.
67. Konopleva, M., Pollyea, D.A., Potluri, J. et al. A Phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML). Blood [56th ASH Annual Meeting and Exposition (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 118.
68. Jones, J., Mato, A.R., Coutre, S.E. et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. 57th Annu Meet Am Soc Hematol (December 5-8, Orlando) 2015] 2015, Abst 715.
69. Stilgenbauer, S., Eichhorst, B., Schetelig, J. et al. LBA-6 venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: Results of the pivotal international phase 2 study. 57th Annu Meet Am Soc Hematol (December 5-8, Orlando) 2015, Abst LBA-6.
70. Ma, S., Brander, D.M., Seymour, J.F. et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. 57th Annu Meet Am Soc Hematol (December 5-8, Orlando) 2015] 2015, Abst 830.
71. de Vos, S., Flowers, C.R., Wang, D. et al. The BCL-2 inhibitor ABT-199 (GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma. Blood [56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014] 2014, 124(21): Abst 1722.
72. Salles, G.A., Boyd, T.E., Morschhauser, F. et al. Updated safety and preliminary efficacy data from a phase 1b study combining venetoclax (GDC-0199, ABT-199) with bendamustine/rituximab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. 57th Annu Meet Am Soc Hematol (December 5-8, Orlando) 2015, Abts 829.
73. Flinn, I., Brunvand, M., Choi, M.Y. et al. Safety and efficacy of a combination of venetoclax (GDC-0199/ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia-results from a phase 1b study (GP28331). 57th Annu Meet Am Soc Hematol (December 5-8, Orlando) 2015, Abst 494.
74. Khaw, S.L., Huang, D.C., Roberts, A.W. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology 2011, 43(6): 525-35.
75. Balakrishnan, K., Gandhi, V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs 2013, 31(5): 1384-94.
76. Del Principe, M.I., Bo, M.D., Bittolo, T. et al. Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica 2016, 101(1): 77-85.
77. Stilgenbauer, S. Prognostic markers and standard management of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2015, 2015: 368-77.